Schering-Plough

New biomarker predicts response to hepatitis C treatment

DURHAM, N.C. -- Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference.

Hepatitis C: No overall difference in sustained viral response in most widely used treatments

DURHAM, N.C. -- Findings from the largest study to date comparing the efficacy of competing treatments for chronic hepatitis C infection (HCV) show that the regimens are similar when it comes to safety and their ability to provoke long-term viral eradication, according to researchers at Duke University Medical Center.

NEJM study points to new era in hepatitis C treatment

NEW YORK (June 4, 2009) -- For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

Researchers Elucidate Machinery of Major Anti-Cancer Drug Target

Researchers have detailed the functioning of an enzyme that is a central component of a signaling pathway important for about 30 percent of cancers. The findings about how the enzyme, called farnesyl transferase (FTase), works could help improve the FTase-inhibiting drugs that pharmaceutical companies are now testing to fight a broad spectrum of cancers.

New biomarker predicts response to hepatitis C treatment

Hepatitis C: No overall difference in sustained viral response in most widely used treatments

NEJM study points to new era in hepatitis C treatment

Researchers Elucidate Machinery of Major Anti-Cancer Drug Target

About us

Recommended